Zimmer Biomet: Will Q4 be the Turning Point?


Zimmer Biomet’s (NYSE: ZBH) US sales have declined every quarter since Q4 2016. After stating their expectations to make significant progress on remediating their supply issues during the first two quarters of 2017, Zimmer management was unable to meet those expectations and delayed their resolution timeline numerous times. The company missed consensus top-line estimates again […]

Read More